CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy

CERo Therapeutics Holdings

05/09/2025 13:16

** Shares of drug developer CERo Therapeutics CERO.O rise 11% to $7.65 premarket

** Co says its experimental blood cancer therapy, CER-1236, received U.S. FDA's "fast track" tag

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** The therapy is being tested in an early stage trial for patients with aggressive forms of acute myeloid leukemia, a type of blood and bone marrow cancer

** Stock down 94% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))